VAUGHAN,
ON, Oct. 3, 2022 /CNW/ -- Bausch + Lomb
Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global
eye health company dedicated to helping people see better to live
better, today announced the U.S. introduction of enhanced Ocuvite
Adult 50+ eye vitamin with 30 micrograms of vitamin D, an
antioxidant proven to help support healthy cell function, which is
key to protecting eye health.* The enhanced Ocuvite vitamin will
replace the currently offered Ocuvite Adult 50+.
"Daily stressors, including smart phones, sunlight and screens,
can impact the eyes. As people age, the natural filter in the eyes
may weaken and leave the eyes more vulnerable to stress," said
Joe Gordon, president, Global
Consumer, Surgical and Vision Care, Bausch + Lomb. "The enhanced
Ocuvite with vitamin D builds upon our original Ocuvite Adult 50+
vitamin to help replenish key nutrients that help protect the
health of the eyes*, particularly as people age. We are committed
to finding ways to enhance our portfolio to continue to address the
evolving needs of eye care professionals and patients."
Many multivitamins do not have all three essential eye health
nutrients (lutein, zeaxanthin and omega-3s) in the right levels to
properly support eye health. Additionally, 42% of Americans have
insufficient levels of vitamin D1, which is important
for eye health.
"Many people do not realize that the eyes lose key nutrients as
they age, which can leave them vulnerable to environmental and
other daily stressors and lead to eye health issues," said
Jeffry Gerson, O.D., Grin Eye Care,
Kansas City, Mo. "I am pleased to
recommend the new enhanced Ocuvite with vitamin D to my patients to
ensure their eyes are provided the ingredients they need to help
counteract the stressors in our daily lives."
The enhanced Ocuvite with vitamin D will be available at major
retailers nationwide in the vitamin aisle starting in October 2022 with a suggested retail price of
$12.85 (50-count bottle).
For more information on Ocuvite Adult 50+ with vitamin D, visit
www.ocuvite.com.
*This statement has not
been evaluated by the Food and Drug Administration. This product is
not intended to diagnose, treat, cure or prevent any
disease.
|
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of
sight for millions of people around the world – from the moment of
birth through every phase of life. Its comprehensive portfolio of
more than 400 products includes contact lenses, lens care products,
eye care products, ophthalmic pharmaceuticals, over-the-counter
products and ophthalmic surgical devices and instruments. Founded
in 1853, Bausch + Lomb has a significant global research and
development, manufacturing and commercial footprint with more than
12,000 employees and a presence in nearly 100 countries. Bausch +
Lomb is headquartered in Vaughan,
Ontario with corporate offices in Bridgewater, New Jersey. For more information,
visit www.bausch.com and connect with us on Twitter,
LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which may
generally be identified by the use of the words "anticipates,"
"hopes," "expects," "intends," "plans," "should," "could," "would,"
"may," "believes," "estimates," "potential," "target," or
"continue" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb's filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties caused by or
relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on Bausch +
Lomb, including but not limited to its project development
timelines, launches and costs (which may increase). Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Bausch + Lomb undertakes no
obligation to update any of these forward-looking statements to
reflect events or circumstances after the date of this news release
or to reflect actual outcomes, unless required by law.
References
- Mercy Medical Center. 42% of Americans are vitamin
deficient. Are you among
them? https://www.cantonmercy.org/healthchat/42-percent-of-americans-are-vitamin-d-deficient/#:~:text=Unfortunately%2C%20about%2042%25%20of%20the,take%20prescription%20medication%20long%20term
Accessed Aug. 26, 2022.
Ocuvite is a trademark of Bausch & Lomb
Incorporated or its affiliates.
© 2022 Bausch & Lomb Incorporated or its affiliates.
OCV.0025.USA.22
Investor Contacts:
|
Media Contacts:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bausch.com
|
lainie.keller@bausch.com
|
|
(908)
927-1198
|
Allison Ryan
|
|
allison.ryan@bausch.com
|
Kristy Marks
|
(877) 354-3705 (toll
free)
|
kristy.marks@bausch.com
|
(908)
927-0735
|
(908)
927-0683
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bausch--lomb-introduces-enhanced-ocuvite-adult-50-eye-vitamin-formulation-with-vitamin-d-301637169.html
SOURCE Bausch + Lomb Corporation